Radyus Research, a global drug development organisation from US, has announced a pivotal strategic partnership with Dt&CRO, a leading South Korean contract research organisation (CRO). This collaboration aims to assist South Korean biotech companies in entering the US market by offering integrated services for drug development planning, regulatory strategy, IND filings, and clinical trial management.

The partnership between Radyus Research and Dt&CRO marks a significant milestone in global biotech collaboration, providing a streamlined pathway for South Korean biotech innovators to access the lucrative US pharma market. Leveraging Radyus Research's expertise in navigating the complex regulatory landscape and managing preclinical and early-stage clinical trials in the United States, South Korean biotech companies can expedite their entry into this key market.

In return, Radyus Research will rely on Dt&CRO for non-GLP and GLP laboratory testing services tailored to Asia based clients. This reciprocal arrangement further enhances the partnership's synergy, fostering a collaborative environment conducive to innovation and growth in the global biotech industry.

The partnership between Radyus Research and Dt&CRO exemplifies a commitment to fostering innovation, collaboration, and global growth in the biotech industry. Together, they aim to accelerate the development and commercialisation of breakthrough therapies that address unmet medical needs and improve patient outcomes worldwide.